Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks! Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks Chimeric Therapeutics Ltd ...

A public company in Durham wants to fast-track the regulatory process for its drug targeting a rare form of aggressive tumors. STORY HIGHLIGHTS Chimerix seeks FDA approval for brain tumor drug ...

Chimerix, Inc.'s dordaviprone shows promise in treating H3 K27M-positive glioma, with a potential FDA approval and commercial launch by Q3 2025. CMRX's strong clinical data and high unmet need in ...

Chimerix plans to submit an NDA for dordaviprone for H3 K27M-mutant glioma, aiming for U.S. approval in Q3 2025. Dordaviprone showed a 28% response rate with a median response duration of 10.4 ...

Tuesday after the biotech company revealed intentions to submit a New Drug Application to the U.S. Food and Drug Authority (FDA) seeking speedy clearance for dordaviprone, a therapy for recurrent ...

Shares of Chimerix have topped 52-week highs in the after-hours session following news the biopharmaceutical company plans to submit Dordaviprone for accelerated approval to the Food and Drug ...

Potential Approval in Q3 2025 in Recurrent H3 K27M-Mutant Diffuse Glioma Submission Plan Follows Productive and Collaborative Pre-NDA Interactions with FDA Company to Host Conference Call on ...

DURHAM, N.C., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of ...